HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made its debut on the Hong Kong Stock Exchange, is set to broaden its business operations to encompass Hebei province. This strategic move follows the company’s successful listing last month and aims to strengthen its presence in the Chinese market.
With existing operations in key Chinese cities such as Shenzhen, Shanghai, Nanchang, and Hong Kong, HighTide is poised to leverage its expertise in NASH treatment to meet the healthcare needs of the Hebei province, further expanding its geographical footprint.- Flcube.com
